Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 7/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928092 | 0.94 | L3MBTL1 (0.68) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL13918749 | 0.92 | KDM4E (0.70) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL11220601 | 0.90 | LMNA (0.85) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL178367 | 0.89 | L3MBTL1 (0.87) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL13577911 | 0.87 | L3MBTL1 (0.97) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL14350257 | 0.86 | KDM4E (0.64) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL24220267 | 0.85 | L3MBTL1 (1.00) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL8208835 | 0.85 | L3MBTL1 (1.00) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL7961787 | 0.85 | L3MBTL1 (1.00) | L3MBTL1LMNAPOLBNPC1RAB9A | |
| SCHEMBL13753746 | 0.84 | KDM4E (0.62) | L3MBTL1LMNAPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495475-A | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LTD (GB) | 2009-07-29 | — | — | CN | claimed |
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | claimed |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| EP-1865959-A2 | PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | claimed |
| WO-2006104917-A2 | PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3954394-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | Centurion BioPharma Corporation (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3310800-B1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | CENTURION BIOPHARMA CORP (US) | 2021-11-17 | — | — | EP | disclosed |
| WO-2019174279-A1 | 1,2-BENZISOSELENAZOL-3(2H)-ONE AND 1,2-BENZISOTHIAZOL-3(2H)-ONE DERIVATIVES AS BETA-LACTAM ANTIBIOTIC ADJUVANTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2019-09-19 | — | — | WO | disclosed |
| US-20190225746-A1 | SURFACE-MODIFIED POLYMERS | NORTH CAROLINA STATE UNIVERSITY | 2019-07-25 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | L3MBTL1 3390/4885LMNA 4544/4885POLB 844/4885 |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | CYP2S1, CYP2F1, CBR3 | L3MBTL1 2300/4885LMNA 4348/4885POLB 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.